Related references
Note: Only part of the references are listed.PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Catherine L. Tan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
Marina Martinez et al.
ONCOIMMUNOLOGY (2021)
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past
Mahdi Abdoli Shadbad et al.
FRONTIERS IN IMMUNOLOGY (2021)
MiRNA-138-5p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis
Mina Rasoolnezhad et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy
Afshin Derakhshani et al.
MOLECULES (2021)
Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine
Afshin Derakhshani et al.
CANCERS (2021)
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Darya Javadrashid et al.
BIOMEDICINES (2021)
Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs
Afshin Derakhshani et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy
Dongli Cai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
CD8+ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway
Jinglian Tao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy
Hongwei Chen et al.
NANOMEDICINE (2020)
Cancer immunotherapy: Pros, cons and beyond
Shuzhen Tan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model
Yanling Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xiaozheng Xu et al.
JOURNAL OF CELL BIOLOGY (2020)
Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
Kristiina Karihtala et al.
CANCERS (2020)
Clinical Challenges of Immune Checkpoint Inhibitors
Maria de Miguel et al.
CANCER CELL (2020)
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Omid Kooshkaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses
Mitra Ghasemi-Chaleshtari et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression
Najwa Skafi et al.
GENE (2020)
Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis
Dong-Jer Shiau et al.
SCIENTIFIC REPORTS (2020)
PD-1+Tregcells: a foe in cancer immunotherapy?
Halil-Ibrahim Aksoylar et al.
NATURE IMMUNOLOGY (2020)
Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy
Samanta C. Funes et al.
AUTOIMMUNITY REVIEWS (2019)
Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes
Nai-Yun Sun et al.
CANCER LETTERS (2019)
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by -TGF antibody to promote durable rejection and immunity in squamous cell carcinomas
E. Dodagatta-Marri et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
Benjamin Y. Kong et al.
FRONTIERS IN ONCOLOGY (2019)
CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production
Junxing Qu et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Jiajing Cai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Takahiro Kamiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway
Xufu Wang et al.
MOLECULAR IMMUNOLOGY (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Jie Deng et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression
Wenwen Xu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways
Arum Park et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Treg-mediated acquired resistance to immune checkpoint inhibitors
Reem Saleh et al.
CANCER LETTERS (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma
Henning Zelba et al.
CANCER IMMUNOLOGY RESEARCH (2019)
SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy
Kuo Jiang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy
Rikito Endo et al.
SCIENTIFIC REPORTS (2019)
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati et al.
BRITISH JOURNAL OF CANCER (2019)
Immune checkpoint blockade opens a new way to cancer immunotherapy
Sanam Sadreddini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Macrophage polarity in cancer: A review
Masoud Najafi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability
Shotaro Korehisa et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Regulatory T cells: a potential target in cancer immunotherapy
Kohei Shitara et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling
Xianglu Ji et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
Matteo Santoni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
Alvaro de Mingo Pulido et al.
CANCER CELL (2018)
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint
Zhen Tao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Treating cancer with microRNA replacement therapy: A literature review
Nayer Hosseinahli et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
Jian-Feng Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
Wei Xiao et al.
JOURNAL OF IMMUNOLOGY (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy
Naoto Nishii et al.
Oncotarget (2018)
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
Felix S. Lichtenegger et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
A novel MDSC-induced PD-1(-)PD-L1(+) B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties
Meng Shen et al.
ONCOIMMUNOLOGY (2018)
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
Liru Wang et al.
ONCOIMMUNOLOGY (2018)
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
Joseph DiDomenico et al.
ONCOIMMUNOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells
Zhiqi Xie et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2018)
Evaluation of the effect of TIM-3 suppression by miR-498 and its effect on apoptosis and proliferation rate of HL-60 cell line
Yaser Moghaddam et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
Ewelina Grywalska et al.
ONCOTARGETS AND THERAPY (2018)
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
Elena Gianchecchi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Immune checkpoint inhibitors in cancer therapy
Eika S. Webb et al.
JOURNAL OF BIOMEDICAL RESEARCH (2018)
Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
P. Hwu et al.
ANNALS OF ONCOLOGY (2017)
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
Yaqing Zhang et al.
GUT (2017)
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-Ll expression on tumor-associated macrophages
Canhua Jiang et al.
IMMUNOBIOLOGY (2017)
MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+T cells through targeting mTOR
Jiao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor-associated macrophages: from basic research to clinical application
Li Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
Sun Hye Kim et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge
Ali Naboush et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2017)
Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
Si-Rui Ma et al.
MOLECULAR CANCER (2017)
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. Guerriero et al.
NATURE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PSGL-1: A New Player in the Immune Checkpoint Landscape
Roberto Tinoco et al.
TRENDS IN IMMUNOLOGY (2017)
MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma
Yaxin Wang et al.
ONCOTARGET (2017)
Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
Jonas R. M. Van Audenaerde et al.
ONCOTARGET (2017)
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
Massimo Giuliani et al.
ONCOTARGET (2017)
VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis
Sabrina Ceeraz et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion
Johan M. J. Van den Bergh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
Carmen Stecher et al.
FRONTIERS IN IMMUNOLOGY (2017)
Strategies to improve the efficacy of Dendritic Cell-Based immunotherapy for Melanoma
Kristian M. Hargadon
FRONTIERS IN IMMUNOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer
Ying Guan et al.
JOURNAL OF BONE ONCOLOGY (2017)
Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma
Laura Boldrini et al.
CANCER CELL INTERNATIONAL (2017)
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
B. El Osta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Feng Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Young-hee Lee et al.
CELL RESEARCH (2017)
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Rigel J. Kishton et al.
CELL METABOLISM (2017)
Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10
Fengyuan Che et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
Jun Wei et al.
NEURO-ONCOLOGY (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Immune checkpoint inhibitors for cancer treatment
Junsik Park et al.
ARCHIVES OF PHARMACAL RESEARCH (2016)
Negative regulation of TIM-3 expression in AML cell line (HL-60) using miR-330-5p
Haniyeh Fooladinezhad et al.
BRITISH JOURNAL OF BIOMEDICAL SCIENCE (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Yu Yao et al.
CLINICAL CANCER RESEARCH (2016)
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
Roberto Tinoco et al.
IMMUNITY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy
Victoria Klepsch et al.
IMMUNOLOGY LETTERS (2016)
Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress antitumor immune responses
Yu Zhang et al.
INTERNATIONAL IMMUNOLOGY (2016)
Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma
Wen-Chun Chang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
Aude G. Chapuis et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
A. Marijne Heeren et al.
MODERN PATHOLOGY (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
Yuta Kondo et al.
ORAL ONCOLOGY (2016)
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7
Matthew M. Halpert et al.
STEM CELLS AND DEVELOPMENT (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu et al.
NATURE COMMUNICATIONS (2016)
PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
Xiao Xiao et al.
CANCER DISCOVERY (2016)
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Lian Zhao et al.
ONCOTARGET (2016)
miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion
Qing Li et al.
ONCOTARGET (2016)
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103+ dendritic cells in late-stage ovarian cancer
Dallas B. Flies et al.
ONCOIMMUNOLOGY (2016)
Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis
Xingwei Jiang et al.
ONCOIMMUNOLOGY (2016)
BTLA identifies dysfunctional PD-1-expressing CD4(+) T cells in human hepatocellular carcinoma
Qiyi Zhao et al.
ONCOIMMUNOLOGY (2016)
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
Emily M. McWilliams et al.
ONCOIMMUNOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery
Shan Qian et al.
RSC ADVANCES (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210
Muhammad Zaeem Noman et al.
CANCER RESEARCH (2015)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1
Siwen Chen et al.
EXPERIMENTAL GERONTOLOGY (2015)
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Zhenxin Wang et al.
IMMUNOLOGICAL INVESTIGATIONS (2015)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
Christopher A. Fuhrman et al.
JOURNAL OF IMMUNOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells
Takanobu Motoshima et al.
ONCOLOGY REPORTS (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma
Wei Guo et al.
TUMOR BIOLOGY (2015)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma
Simon Jasinski-Bergner et al.
ONCOIMMUNOLOGY (2015)
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Danielle M. Lussier et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Profiling of primary peripheral blood-and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia
Stella E. Autenrieth et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2015)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lei Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Molecular regulation of effector and memory T cell differentiation
John T. Chang et al.
NATURE IMMUNOLOGY (2014)
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
A. Q. Butt et al.
ONCOGENE (2014)
Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
Valli De Re et al.
PLOS ONE (2014)
MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3
Jun Zhao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Joel Crespo et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
Noa Stanietsky et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Jinpu Yu et al.
JOURNAL OF IMMUNOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Jing Yan et al.
PLOS ONE (2013)
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Kaori Sakuishi et al.
ONCOIMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Regulatory T Cells: Mechanisms of Differentiation and Function
Steven Z. Josefowicz et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
Saar Gill et al.
BLOOD (2012)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
Anja Heinemann et al.
CANCER RESEARCH (2012)
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
Hyo Jin Park et al.
CELLULAR IMMUNOLOGY (2012)
MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their Function
Hussein Fayyad-Kazan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation
Naoto Sato et al.
ONCOLOGY REPORTS (2012)
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
Xin Gao et al.
PLOS ONE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3
Thomas Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph et al.
CLINICAL CANCER RESEARCH (2010)
HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer
Maureen P. Martin et al.
IMMUNOGENETICS (2010)
BTLA mediates inhibition of human tumor-specific CD8(+) T cells that can be partially reversed by vaccination
Laurent Derre et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes
Kutlu G. Elpek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Immune Therapy for Cancer
Michael Dougan et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections
Sang-Jun Ha et al.
IMMUNOLOGICAL REVIEWS (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Natural killer cells, viruses and cancer
A Cerwenka et al.
NATURE REVIEWS IMMUNOLOGY (2001)
Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158)
EO Long et al.
IMMUNOLOGICAL REVIEWS (2001)
Share Paper
